What is TACGen?
TACGen is a specialized provider of molecular biology products and services, essential for genetic analysis and manipulation. Their comprehensive offerings include plasmids, DNA preparation, high throughput sequencing, and custom cloning solutions, catering to the research and biotechnology sectors. The company also excels in advanced services such as epigenetic modulator discovery and various sequencing techniques, underscoring its commitment to delivering high-quality results and robust customer support to scientists and researchers.
How much funding has TACGen raised?
TACGen has raised a total of $17K across 1 funding round:
Debt
$17K
Debt (2021): $17K with participation from PPP
Key Investors in TACGen
PPP
Public-Private Partnership
What's next for TACGen?
With the recent injection of moderate growth capital, TACGen is poised to accelerate its expansion and further solidify its market position. The Series A/B growth stage funding indicates a strategic focus on scaling operations, enhancing product development, and potentially broadening its service portfolio. This investment will likely enable TACGen to deepen its impact within the research and biotechnology communities, driving innovation in genetic analysis and manipulation.
See full TACGen company page
